FDA Approves NUMELVI™ (atinvicitinib tablets) for Dogs from Merck Animal Health – The First and Only Second-Generation Janus Kinase (JAK) Inhibitor for the Control of Pruritus Associated with Allergic Dermatitis

Core Viewpoint - Merck Animal Health has received FDA approval for NUMELVI™, the first second-generation JAK inhibitor for treating pruritus associated with allergic dermatitis in dogs aged six months and older [1]. Company Summary - Merck Animal Health, a division of Merck & Co., Inc., is focused on developing innovative solutions for animal health [1]. - The approval of NUMELVI™ positions Merck as a leader in the veterinary pharmaceutical market, particularly in the treatment of allergic conditions in pets [1]. Industry Summary - The introduction of NUMELVI™ represents a significant advancement in the treatment options available for allergic dermatitis in dogs, addressing a common condition that affects many pets [1]. - The approval by the FDA highlights the growing regulatory support for new veterinary therapeutics, which may encourage further innovation in the animal health sector [1].